Indonesia

AI Citation Summary

• Country: Indonesia
• Product line: Medical devices
• Regulator / source: Market structure: Indonesia operates a strong distributor-led market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ability to execute locally through a qualified, IDAK-licensed distributor (or an independent license-holder) are essential for successful market entry.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Indonesia's medical devices are regulated by the Ministry of Health (Kementerian Kesehatan / Kemenkes) through its Regalkes electronic system, under an ASEAN Medical Device Directive (AMDD)-aligned, risk-based licensing framework (Permenkes No. 62/2017 as the underlying izin edar rule, restructured inside the OSS risk-based business-licensing regime of Permenkes No. 11/2025). Devices are classified Class A–D by risk, the marketing license is called Izin Edar / NIE (Nomor Izin Edar) — issued as AKL for imported devices — and it can only be held by a locally licensed Indonesian entity (an IDAK holder), never directly by the foreign manufacturer. Practical end-to-end timelines run roughly 1–2 months for a straightforward Class A device up to 4–6 months for Class D, license validity is 5 years, and the government evaluation fee (PNBP) ranges roughly IDR 1.5–5 million (about US$95–350) depending on class.
• Key fees: Indonesia's medical devices are regulated by the Ministry of Health (Kementerian Kesehatan / Kemenkes) through its Regalkes electronic system, under an ASEAN Medical Device Directive (AMDD)-aligned, risk-based licensing framework (Permenkes No. 62/2017 as the underlying izin edar rule, restructured inside the OSS risk-based business-licensing regime of Permenkes No. 11/2025). Devices are classified Class A–D by risk, the marketing license is called Izin Edar / NIE (Nomor Izin Edar) — issued as AKL for imported devices — and it can only be held by a locally licensed Indonesian entity (an IDAK holder), never directly by the foreign manufacturer. Practical end-to-end timelines run roughly 1–2 months for a straightforward Class A device up to 4–6 months for Class D, license validity is 5 years, and the government evaluation fee (PNBP) ranges roughly IDR 1.5–5 million (about US$95–350) depending on class.
• Local requirement: Local distributor / AKL holder - Foreign manufacturers usually apply and maintain product licences through a licensed local distributor / importer holding IDAK and CDAKB - Contracts should lock down AKL / NIE control, licence transfer, import permits, PMS, recall, after-sales, termination, and handover
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Direct Answer

Indonesia's medical devices are regulated by the Ministry of Health (Kementerian Kesehatan / Kemenkes) through its Regalkes electronic system, under an ASEAN Medical Device Directive (AMDD)-aligned, risk-based licensing framework (Permenkes No. 62/2017 as the underlying izin edar rule, restructured inside the OSS risk-based business-licensing regime of Permenkes No. 11/2025). Devices are classified Class A–D by risk, the marketing license is called Izin Edar / NIE (Nomor Izin Edar) — issued as AKL for imported devices — and it can only be held by a locally licensed Indonesian entity (an IDAK holder), never directly by the foreign manufacturer. Practical end-to-end timelines run roughly 1–2 months for a straightforward Class A device up to 4–6 months for Class D, license validity is 5 years, and the government evaluation fee (PNBP) ranges roughly IDR 1.5–5 million (about US$95–350) depending on class.

Country Overview

• Market structure: Indonesia operates a strong distributor-led market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ability to execute locally through a qualified, IDAK-licensed distributor (or an independent license-holder) are essential for successful market entry.
• Scale and demand: Indonesia is Southeast Asia's largest population (~280 million) and one of the region's fastest-growing device markets, driven by JKN/BPJS national health insurance expansion, hospital-network growth, and rising private diagnostic demand.
• Regulatory maturity: Medium. The classification system is harmonized with ASEAN AMDD, but execution runs through a domestic licensing chain (AKL/NIE, IDAK, CDAKB) that is materially different from the EU authorized-representative model, and government procurement carries its own local-content (TKDN) layer.

Quick Reference

Market-Entry Logic

Indonesia medical device entry should be separated into five layers: Kemenkes / Regalkes product licensing, local distributor as AKL / NIE holder, importation and Bahasa Indonesia labeling, LKPP / e-catalogue / JKN public procurement, and TKDN / local-content plus after-sales service. Foreign manufacturers generally cannot control submission and import execution directly; the local distributor's registration, importation, tendering, engineering, and service capability determines the quality of market entry.

For foreign manufacturers, Indonesia is not a simple "get AKL then sell" market. AKL/NIE is the compliance entry point; e-catalogue, TKDN, hospital access, after-sales engineering, and licence-holder control are the variables behind scale.

Main Players and Channel Map

Channel due diligence should separately verify whether the distributor can actually maintain AKL/NIE and CDAKB; whether it can access LKPP / e-catalogue and target hospitals; whether it has engineers, spare parts, application training, and service SLAs; and whether it can handle importation, FX, inventory, and government payment cycles.

Development Trends

1. Kemenkes digital licensing continues to strengthen: Regalkes / AKL / NIE is the foundational device-entry system under the OSS risk-based framework (Permenkes No. 11/2025), and account, licence-holder, and transfer arrangements affect long-term commercial control.
2. e-catalogue and JKN raise public-channel thresholds: Public hospital procurement increasingly values price, supply continuity, compliant catalogue access, TKDN local-content scoring, and local service. Registration approval alone is not enough to create government volume.
3. TKDN and localisation increasingly gate government procurement: Since 2022-era tightening, thousands of imported device models across dozens of categories have been excluded from e-Katalog listing for falling short of local-content thresholds; local content, assembly, service, and supply-chain commitments now materially affect competitiveness in government projects.
4. Halal certification has become a hard compliance deadline, not a "may apply" note: Government Regulation No. 42/2024 brings medical devices into the mandatory Halal regime on a class-by-class schedule starting with Class A on 18 October 2026.
5. After-sales service becomes a premium-device access condition: Imaging, IVD, surgical, ICU / OR, and dental equipment require installation, calibration, maintenance, spare parts, and clinical-application support.
6. Distributor-control risk is significant: If the distributor controls AKL/NIE, import permits, and customer relationships, later distributor changes, certificate transfer, and supply continuity may depend heavily on contract terms — the license does not automatically follow the manufacturer.

Regulatory Authority

• Primary Authority: Ministry of Health (Kementerian Kesehatan / Kemenkes), Directorate General of Pharmaceuticals and Medical Devices (Direktorat Jenderal Farmasi dan Alat Kesehatan / Farmalkes)
• Submission portal: Regalkes (https://regalkes.kemkes.go.id)
• Halal authority: BPJPH (Badan Penyelenggara Jaminan Produk Halal) (https://bpjph.halal.go.id)
• Key regulations:
  • Permenkes No. 62/2017 — Izin Edar Alat Kesehatan, Alat Kesehatan Diagnostik In Vitro dan Perbekalan Kesehatan Rumah Tangga (the underlying medical device / IVD marketing-license regulation; 5-year validity is set out in Article 24)
  • Permenkes No. 11/2025 — Standar Kegiatan Usaha dan Standar Produk/Jasa pada Penyelenggaraan Perizinan Berusaha Berbasis Risiko Subsektor Kesehatan (current risk-based OSS licensing framework that now houses domestic and imported device Izin Edar as part of the health-sector business-licensing standard; enacted 3 October 2025)
  • Health Law No. 17/2023 (Article 319) and Government Regulation No. 28/2025 (Article 416) — statutory basis for CDAKB (good distribution practice) obligations and penalties
  • Permenkes No. 4/2014 — baseline CDAKB (Cara Distribusi Alat Kesehatan yang Baik) regulation
  • Law No. 33/2014, Presidential Regulation No. 6/2023, and Government Regulation No. 42/2024 — Halal Product Assurance (JPH) framework now covering medical devices
• Key local terms: AKL (imported-device product licence) / AKD (domestic-device product licence) / NIE (Nomor Izin Edar — the licence number itself); IDAK (Izin Distribusi Alat Kesehatan, the distributor entity licence — successor naming to IPAK/SDAK); CDAKB (Cara Distribusi Alat Kesehatan yang Baik, good distribution practice); PJT (Penanggung Jawab Teknis, qualified technical person in charge); LKPP / e-catalogue; TKDN.

Element 1 — Device Classification and Pathway Branching

Classification follows ASEAN Medical Device Directive (AMDD) risk rules, harmonized with GHTF/IMDRF principles; IVDs use the same four-tier structure with IVD-specific classification rules (see the IVD section below).

Pathway Branching Table

Practical note: Formal-clock figures and practical-total figures come from different secondary sources and are not always fully reconcilable — Kemenkes has not published a single authoritative day-count table in the sources checked for this page. Treat both as directional ranges, and confirm the current expected timeline for your specific product with your Regalkes account / local license holder before committing to a launch date. The 2022-vintage ~34-SKU simplified-notification list should also be re-verified against the current Regalkes portal, since it predates Permenkes No. 11/2025. 【待核验：现行 Permenkes 11/2025 下简化备案清单是否仍为原 34 项，需在 Regalkes 门户复核】

Element 2 — License-Holder Logic: Who Controls Your AKL/NIE

This is the single most consequential structural decision for a foreign manufacturer entering Indonesia, because the Izin Edar (AKL/NIE) cannot be held by the manufacturer itself — only a locally licensed Indonesian entity holding an IDAK (distributor license) and CDAKB (good distribution practice) certification can hold it. There are three practical ways to structure who that entity is.

Three Options

What Happens When You Switch Distributors

• Under Option 1 (own subsidiary): Switching a commercial/sales distributor does not touch the license at all, because the manufacturer's own entity holds the Izin Edar. This is the structural reason large multinational device companies with sustained Indonesia volume often eventually localize.
• Under Option 2 (distributor-held): Because the license is registered to the distributor's legal entity and is treated as effectively non-transferable, changing distributors in practice means re-registering the product under the new distributor's IDAK — a process reported to take 6–12 months and to require the outgoing distributor's cooperation to formally close out its registration. This is the scenario the market-entry logic and channel-map sections above flag as "distributor-control risk."
• Under Option 3 (neutral license holder): The manufacturer can add, replace, or run multiple commercial distributors without re-registering the product, because the license sits with the neutral holder rather than any single seller — this is the model's main commercial argument.

Decision guidance: Low-to-moderate volume market testing typically favors Option 2 for speed, accepting the switching-cost risk as a known trade-off to be managed contractually (see Market Entry Strategy below). Sustained strategic commitment to Indonesia — multiple product lines, multi-year horizon, sensitivity to distributor lock-in — favors Option 1 or Option 3. Whichever option is chosen, the distribution agreement should explicitly address technical-file/dossier ownership, handover obligations, PMS and recall responsibility, and a defined transition timeline if the relationship ends. 【待核验：第三方持证服务的年度托管费无官方公开费率，需向具体服务商索取报价】

Element 3 — License Validity and Review Timelines

See Element 1's pathway table above for the class-by-class evaluation-clock and practical-timeline ranges.

Element 4 — In-Country License-Holder Obligations

The IDAK-holding entity (whether the manufacturer's own subsidiary, a commercial distributor, or a neutral license holder) carries binding, ongoing obligations toward Kemenkes — these are not one-time registration steps.

Practical note: Because these obligations sit with the license holder, not the manufacturer, manufacturers using Option 2 or Option 3 above should contractually require evidence of current CDAKB certification, PJT staffing, and warehouse compliance before signing, and should build periodic compliance-verification rights into the agreement.

Element 5 — Fee Model

Indonesia's device-registration cost structure combines fixed government (PNBP) fees with variable commercial/service costs. The figures below are the most specific numbers found in accessible secondary sources; official current tariffs should be reconfirmed on the Regalkes portal before budgeting, since PNBP schedules are periodically revised.

Note: Line items marked "not officially published" reflect the absence of a public Kemenkes tariff schedule for commercial/service costs in the sources reviewed for this page — these are market-priced services, not government fees, and vary by vendor and product complexity. 【待核验：CDAKB 认证/审计准备费、第三方持证年度托管费、翻译费均无官方公开费率，正式立项前需向本地代理/持证服务商索取书面报价】

Element 6 — Registration Forms: Notification vs. Full Registration

The distinction matters commercially: the product license (NIE/AKL) and the entity license (IDAK) are separate approvals that must both be current and correctly matched — an entity can hold a valid IDAK and still be blocked from selling a specific device if that device's NIE has lapsed, and vice versa.

Element 7 — Special Requirements

Halal Certification (Class-by-Class Mandate)

Indonesia's Halal Product Assurance regime, originally built around food, beverages, and cosmetics, has been formally extended to medical devices under Government Regulation (PP) No. 42/2024, building on Law No. 33/2014 and Presidential Regulation No. 6/2023.

Officially confirmed (BPJPH, primary source): Starting 18 October 2026, a defined list of product categories — including "consumable goods," which BPJPH's own public guidance explicitly names as covering Class A risk medical devices — must carry Halal certification to remain on the Indonesian market. BPJPH's head has publicly stated there will be no extension of this date.

Staggered schedule by risk class (corroborated by two independent secondary sources citing PP 42/2024, exact calendar day not independently confirmed for B/C/D):

Scope note: Requirements generally attach to devices that contain or come into contact with animal-derived materials or other substances subject to Halal assessment. One secondary source states that wholly synthetic/metallic devices and software-only (SaMD) products are exempt from certification — this exemption claim is not independently confirmed in the official text accessible for this page. 【待核验：具体豁免范围（如纯合成/金属器械、纯软件 SaMD 是否豁免）未能在可访问的官方文本中独立核实，建议在临近 2026-10-18 前直接向 BPJPH / Kemenkes 书面核实产品适用性,因不合规后果可包括下架和清关受阻】

Certification is administered by BPJPH, with inspection carried out by accredited Halal Inspection Agencies (Lembaga Pemeriksa Halal / LPH), such as LPPOM MUI.

Bahasa Indonesia Labeling and IFU

• Bahasa Indonesia labeling is mandatory for all medical devices placed on the Indonesian market; CE- or FDA-compliant English-only labeling is not sufficient on its own.
• Required label content typically includes manufacturer information, local distributor/license-holder information, product name, lot/batch and serial number, expiry date, IFU reference, and (where applicable) the Halal mark.
• Plan for translation and print-production lead time — secondary-source guidance commonly suggests budgeting 6–8 weeks — and keep the Bahasa dossier updated in lockstep with any home-market labeling change.

SNI (Standar Nasional Indonesia)

Certain product categories are subject to mandatory SNI certification. SNI is entirely independent from CE marking and cannot be waived by presenting a CE certificate; it must be identified and managed as a separate compliance stream, ideally screened for at the same time the device's risk class is confirmed, so it does not become a late-stage bottleneck to commercialization.

Element 8 — Leveraging Existing CE / FDA / NMPA Approvals (Shortcut Pathways)

Quick Assessment

EU CE (MDR/MDD/IVDR)

• Recognition mechanism: A valid CE certificate issued by an EU-designated Notified Body is accepted as core supporting evidence within the ASEAN CSDT technical dossier, demonstrating that the product has already undergone systematic risk assessment under a recognized regulatory framework.
• Practical effect: There is no formal expedited or abbreviated registration route for CE-marked products in Indonesia, but applications backed by a valid, current CE certificate tend to receive fewer technical queries and move more smoothly through review.
• Key caveats: Self-declared CE marks (no Notified Body involvement) carry no equivalent weight. SNI certification, where applicable, remains a mandatory independent requirement CE cannot waive. Bahasa Indonesia labeling and local compliance documentation must still be prepared separately.

US FDA (510(k) / De Novo / PMA)

• Recognition mechanism: FDA clearance or approval documents can be presented as evidence of review by a major, high-standard reference regulator, strengthening the overall credibility of the Regalkes application.
• Practical effect: The impact is most significant for Class C and Class D (high-risk) devices — submitting PMA-level approval documentation can reduce the volume of clinical-evidence queries, making this the highest-value scenario for leveraging FDA approval in Indonesia. Class A/B products with FDA 510(k) clearance also tend to see improved review efficiency.
• Key caveats: There is no universal, formally codified fast track triggered by FDA evidence alone; the practical benefit depends on product risk and reviewer judgment. Present FDA materials with a clear comparative narrative to Indonesian requirements rather than simply attaching the decision letter.
• IVD-specific nuance — this is a prerequisite, not just an accelerator: For certain high-risk IVD categories, prior approval from a recognized reference country (EU, US, Japan, and others) is reported to be a mandatory precondition before an Indonesian IVD registration application can even be submitted — not an optional acceleration. HIV reagents and test kits carry an additional, specific requirement: performance test reports generated at Indonesia's own national reference laboratory hospital (RSCM), regardless of foreign approval status.

China NMPA

• Recognition mechanism: Kemenkes / Regalkes does not recognize NMPA registration as a formal reference-market approval; it carries no core evidentiary weight in the Indonesian technical dossier.
• Practical effect: Despite deepening Indonesia–China trade ties generally, there is no formal mutual-recognition mechanism in the medical device sector. NMPA certificates offer essentially no shortening of review time or simplification of documentation.
• Key caveats: If a product holds both CE and FDA approvals, present those as the primary reference-market evidence; an NMPA certificate can be included as supplementary market-background information but should not be positioned as core technical evidence.

ASEAN CSDT — the Regional Format That Actually Helps

• Indonesia's registration dossier follows the ASEAN Common Submission Dossier Template (CSDT), defined under Annex 4 of the AMDD, structured around six sections: administrative data; device description and classification; technical documentation; quality management system evidence; performance and safety data; and labeling/IFU.
• Because Singapore (HSA), Malaysia (MDA), and other ASEAN AMDD signatories use the same CSDT structure, a dossier built for one ASEAN market can generally be reused for Indonesia with Indonesia-specific additions (Bahasa translation, local labeling, Halal marking where applicable) rather than being rebuilt from scratch — this is a genuine, structural time-saver even though it is not a formal reliance or mutual-recognition agreement.
• No local clinical trial is generally mandated where substantial international clinical evidence already exists (e.g., backing a CE or FDA submission); Kemenkes may still request local clinical evaluation or validation data for genuinely novel, high-risk (Class D) devices, or for certain IVDs, to confirm performance in the local population.

Practical Recommendations

1. Lead with the strongest reference-market file: Products holding both CE and FDA approval should present both clearly in the CSDT Technical Summary, with notarized/legalized originals attached, to establish a "multi-major-market approved" baseline.
2. Treat SNI and Halal as independent tracks: Neither is waived by CE, FDA, or any foreign approval; screen for applicability early and manage them on their own project timelines.
3. Start Bahasa Indonesia labeling work early: Regardless of foreign-approval status, plan 6–8 weeks for translation and print production, and keep the file synchronized with any home-market label changes.
4. Build the CSDT dossier ASEAN-wide, not Indonesia-only: If the region is a strategic target, structure the technical dossier for CSDT reuse across Indonesia, Singapore, and Malaysia from the outset.
5. Select your license-holder structure deliberately: See Element 2 above — reference-market approvals accelerate the technical review, but they do not solve the commercial control question of who holds the license.

IVD-Specific Requirements

• Classification: In vitro diagnostic devices use the same four-tier Class A–D structure as general medical devices, harmonized with AMDD/GHTF principles, but with IVD-specific classification rules (e.g., self-testing, blood-screening, and infectious-disease IVDs are weighted toward higher risk classes).
• Reference-country precondition: For certain IVD categories, prior approval from a recognized reference country (EU, US, Japan, and others) is required before an Indonesian IVD application can be submitted — treat this as a gating prerequisite, not a discretionary accelerator.
• HIV reagents and kits — additional local testing: High-risk IVDs, specifically HIV reagents and test kits, require performance test reports generated at Indonesia's National Reference Laboratory Hospital (RSCM, Rumah Sakit Cipto Mangunkusumo), in addition to any foreign approval already held.
• Timeline (secondary-source estimate): Class A ~30 days; Class B ~60 days; Class C ~60 days; Class D ~90 days (formal evaluation window; add administrative/portal time as with general devices).
• Fee (secondary-source estimate): Class A ~US$115; Class B ~US$230; Class C ~US$230; Class D ~US$340 — confirm against the current official PNBP tariff before budgeting.
• License validity: Up to 5 years, consistent with general-device Izin Edar validity.
• License holder: Must be a locally licensed Indonesian distributor (IDAK holder); the license is non-transferable and can only be held by one entity per product at a time — the same license-holder decision framework in Element 2 applies to IVDs.

Software as a Medical Device (SaMD)

• Regulatory status: As of the sources accessible for this page, Kemenkes has not published a dedicated, standalone SaMD regulation; standalone software is instead regulated through the existing medical device framework, classified Class A–D by intended use and risk, consistent with the ASEAN AMDD's general risk-classification logic. 【待核验：现行是否已有独立 SaMD 专项规则或仅并入既有 Class A-D 框架，建议直接向 Farmalkes 核实最新状态，尤其是 AI/算法类产品的分级边界】
• Standards expectation: An IEC 62304 software-lifecycle certificate from an accredited laboratory is commonly required as part of the technical dossier, evidencing controlled software development and maintenance practices.
• Registration pathway: SaMD follows the standard Regalkes/CSDT submission pathway, with software-specific technical documentation layered on top of the standard dossier — software architecture description, cybersecurity risk assessment, clinical-evaluation evidence, and intended-use documentation.
• Labeling/IFU: A Bahasa Indonesia IFU is still required and must clearly explain how to obtain, install, and operate the software, in addition to its intended clinical use.
• AI / algorithm-based products: No specific, codified rule set for AI- or machine-learning-based SaMD (e.g., adaptive algorithms, continuous-learning models) was found in the sources accessible for this page. Treat novel AI-driven products conservatively, plan for possible additional technical scrutiny or a request for local validation data, and confirm the current position directly with Farmalkes/Kemenkes before finalizing a regulatory strategy. 【待核验】

E-Catalogue, JKN, and TKDN Procurement

• e-Katalog / INAPROC as the mandatory government channel: Public hospital, BPJS Kesehatan/JKN, and other government medical-device procurement is conducted through LKPP's national e-catalogue system, which is in transition to e-Katalog version 6 (INAPROC) as part of Indonesia's broader digital procurement reform.
• TKDN local-content threshold materially restricts catalogue access: Following 2022-era policy tightening, the government excluded more than 5,400 imported device models across 79 product categories from the public e-Katalog unless they met a minimum 40% domestic (Indonesian) content threshold. Since that tightening, the import share of listed government-catalogue devices reportedly fell from roughly 92% to roughly 52%.
• Categories without a qualifying local alternative: Products in categories where no adequate domestic substitute exists may still gain e-Katalog access case-by-case, but manufacturers should expect to substantiate the absence of a compliant local alternative as part of the listing process.
• JKN/BPJS volume depends on more than registration: Even a fully registered, NIE-approved device needs e-Katalog listing, competitive pricing, and demonstrated supply continuity to convert into meaningful public-hospital volume — registration approval alone does not create government-channel sales.
• Strategic implication: If government/public-hospital volume is a priority channel, assess TKDN exposure early — local assembly, local component sourcing, or an in-country manufacturing/joint-venture partnership can materially change catalogue eligibility and competitiveness relative to importing a fully finished device.

Import and Customs Requirements

• Import clearance is handled through the licensed local entity using its import license (Angka Pengenal Importir, API); the local IDAK/CDAKB holder — not the foreign manufacturer — is the party of record with customs.
• Bahasa Indonesia labeling is required for products placed on the Indonesian market; CE or FDA labeling in English alone is not sufficient.
• HS code declarations and customs compliance are managed by the local importer; the customs classification should be checked against the registered device scope to avoid mismatches that trigger clearance delays.
• Import documentation should be planned in parallel with (not after) NIE registration, since import execution depends on the local entity's IDAK/CDAKB status remaining current.

Post-Market Surveillance

• Adverse-event reporting and recall responsibility rest with the local Izin Edar holder as the party accountable to Kemenkes, regardless of which of the three Element 2 license-holder structures is in place — this is a further reason the license-holder contract needs explicit PMS and recall obligations spelled out.
• CDAKB traceability obligations require the license holder to maintain batch/lot traceability records sufficient to support a recall if one is ordered.
• Kemenkes / Regalkes may require periodic safety updates or field safety corrective actions consistent with the product's risk class and any post-market signals.
• Penalties for non-compliance with distribution/CDAKB obligations, including inadequate PMS or recall execution, can reach statutory maximums of up to 15 years' imprisonment and fines up to IDR 1.5 billion under Health Law No. 17/2023 — a materially higher stakes regime than a purely administrative penalty framework, and a strong argument for verifying the license holder's compliance posture before signing.

Market Access Channels

• Public hospital / JKN procurement: The most consequential channel by volume; requires e-Katalog listing, competitive pricing, TKDN positioning, and demonstrated supply continuity — see the E-Catalogue section above.
• Private hospitals / diagnostic networks: Faster-moving, more flexible procurement decisions; a practical early reference-site channel for premium or innovative devices ahead of a broader public-sector push (e.g., Siloam Hospitals, Mitra Keluarga, Hermina, Mayapada, Primaya, Prodia).
• Distributor / dealer networks: B2B distribution dominates outside direct hospital tenders; distributor engineering, spare-parts, and training capability is a differentiator for imaging, IVD, surgical, and dental equipment.
• Direct government tenders: Conducted alongside the e-Katalog system for larger or specialized procurements; valid Izin Edar and, where applicable, TKDN compliance are prerequisites.

Market Entry Strategy and Key Risks

Recommended approach:

• High-value, high-risk-class products (Class C/D): Prioritize a distributor or license-holder structure (Element 2) with demonstrated Regalkes submission experience for that risk class, and lock down PMS, recall, and transition rights in the contract from day one, given the higher compliance stakes and the greater difficulty of unwinding a Class D registration.
• Lower-risk, higher-volume products (Class A/B): The simplified-notification pathway (where the SKU qualifies) can materially compress time-to-market; confirm current eligibility on the Regalkes portal before assuming a product qualifies.
• Government-channel ambitions: Treat TKDN assessment as a parallel workstream to registration, not an afterthought — local-content shortfalls can block e-Katalog listing regardless of registration status.
• Halal-affected product lines: If your device contains or contacts animal-derived materials and falls in Class A, treat 18 October 2026 as a hard external deadline, not a planning buffer — BPJPH has publicly stated there will be no extension.

Key risks:

1. Distributor lock-in: If the distributor holds the license (Option 2 in Element 2), switching later is reported to take 6–12 months and requires the outgoing distributor's cooperation — negotiate transition and dossier-handover rights before signing, not after a dispute arises.
2. Halal-deadline exposure: For Class A devices with animal-derived or Halal-relevant components, the 18 October 2026 deadline carries real market-access consequences (products can reportedly be pulled from shelves or held at customs) — verify applicability directly with BPJPH/Kemenkes well in advance rather than assuming exemption. 【待核验：具体产品的清真适用性判定建议官方书面核实】
3. TKDN exclusion from government channels: A device that does not meet the 40%-type local-content threshold for its category may be structurally excluded from e-Katalog regardless of clinical merit or registration status.
4. CDAKB/IDAK compliance gaps at the license-holder level: Because these obligations legally sit with the license holder, a distributor's compliance failure (warehouse, PJT staffing, audit) is a direct business risk to the manufacturer's ability to keep selling.
5. Timeline uncertainty from query rounds: Supplementary-information requests are the most commonly cited cause of registration delay beyond the formal evaluation clock — build buffer into launch planning, particularly for Class C/D.

Practical tips:

• Confirm current Regalkes account, dossier format, and (where relevant) simplified-notification SKU-list status directly on the portal — regulation numbers and administrative lists in this space have changed materially in recent years (Permenkes 62/2017 → Permenkes 11/2025).
• Build the technical dossier in ASEAN CSDT format from the outset if Indonesia is part of a broader Southeast Asia entry plan, to capture reuse value across Singapore, Malaysia, and other AMDD signatories.
• Treat Bahasa Indonesia labeling, SNI (where applicable), and Halal certification (where applicable) as three independent compliance tracks running in parallel with registration, not sequential steps after NIE approval.
• For any high-risk IVD category, confirm reference-country-approval and RSCM local-testing requirements before finalizing a submission timeline, since these can be gating rather than optional.

FAQ

Q: Does a foreign manufacturer need a local partner, and who actually holds the license?

A: Yes. A foreign manufacturer cannot hold an Izin Edar (AKL/NIE) directly — only a locally licensed Indonesian entity holding an IDAK (distributor license) and CDAKB (good distribution practice) certification can register and hold the product license. See Element 2 for the three ways to structure who that entity is.

Q: What are the three ways to structure the license-holder relationship, and which is best?

A: (1) Establish your own PT PMA subsidiary as the IDAK/license holder — full control, but a high capital commitment commonly cited around IDR 10 billion (~US$600,000–750,000) under general foreign-investment rules, plus months of setup. (2) Let your commercial distributor hold the license — fastest and lowest-capital route, but switching distributors later is reported to require 6–12 months of re-registration. (3) Use an independent, neutral third-party license holder — moderate cost via an annual custodianship fee, but preserves the ability to add or change commercial distributors without re-registering. There is no universally "best" option; it depends on capital availability, expected volume, and how much distributor-switching flexibility matters to your strategy.

Q: How long does registration actually take in practice?

A: A qualifying simplified-notification Class A device can clear in as fast as 16 working days (up to 36). A full Class A registration runs roughly 1–2 months practical. Class B/C typically run 3–4 months practical, and Class D typically runs 4–6 months practical, with supplementary-information query rounds being the most commonly cited cause of delay beyond these ranges.

Q: How much should a company budget in total?

A: Regulatory-consultancy secondary sources cite an all-in reference range of roughly US$6,000–35,000 for a single device through one risk class, covering government PNBP fees, local representation, consulting, translation, and testing. This is a secondary-source estimate, not an official Kemenkes figure — several component costs (CDAKB audit preparation, translation, license-holder service fees) have no published official tariff and should be quoted directly by vendors before budgeting.

Q: What is the Indonesia Halal certification deadline for medical devices, and does it apply to my product?

A: Class A risk medical devices must be Halal-certified by 18 October 2026, confirmed by BPJPH with no stated extension. Classes B, C, and D follow a later staggered schedule (secondary sources cite 2029, 2034, and 2039 respectively, year-level only, under PP No. 42/2024). Applicability generally turns on whether the device contains or contacts animal-derived materials; the scope of any exemption for wholly synthetic or software-only devices is not independently confirmed in the sources reviewed for this page, so confirm directly with BPJPH/Kemenkes if your product's status is unclear — the consequences of missing this deadline can include removal from shelves and customs holds.

Q: Does an existing CE or FDA approval speed up Indonesian approval?

A: Both are accepted as strong supporting technical evidence in the ASEAN CSDT dossier and commonly reduce the number of technical queries, but neither triggers a formal, codified fast track. FDA approval carries the most practical weight for Class C/D devices, where PMA-level documentation can meaningfully reduce clinical-data queries. For certain high-risk IVD categories, reference-country approval (EU/US/Japan, etc.) is not optional — it is a mandatory precondition before the Indonesian IVD application can be submitted at all. China NMPA is not recognized as a reference market and provides essentially no acceleration.

Q: What happens if we need to change distributors later?

A: It depends on the license-holder structure chosen at the outset (Element 2). If the distributor holds the license, changing distributors is reported to require re-registering the product under the new distributor's IDAK — a process that can take 6–12 months and needs the outgoing distributor's cooperation. If the manufacturer's own subsidiary or a neutral third-party license holder holds the license instead, commercial distributors can generally be changed without touching the product registration.

Q: Is Bahasa Indonesia labeling always mandatory, and how much lead time should we plan?

A: Yes — Bahasa Indonesia labeling and IFU are mandatory for every device placed on the Indonesian market regardless of CE/FDA status; English-only labeling is not sufficient. Secondary-source guidance commonly suggests budgeting 6–8 weeks for translation and print production, run in parallel with (not after) the registration process.

Q: Does government/JKN procurement require local manufacturing (TKDN)?

A: Not universally, but TKDN (local-content) thresholds — commonly cited around a 40% minimum for many device categories — govern which products can be listed on the mandatory e-Katalog procurement system that public hospitals and JKN/BPJS purchase through. Thousands of imported device models have reportedly been excluded from listing for falling short of this threshold since 2022-era tightening. If public-sector volume is a strategic priority, assess TKDN exposure and local-sourcing or assembly options early, in parallel with registration.

Official Sources and Verification Date

• Ministry of Health / Regalkes (submission portal): https://regalkes.kemkes.go.id
• Directorate General of Pharmaceuticals and Medical Devices (Farmalkes): https://farmalkes.kemkes.go.id
• BPJPH (Halal Product Assurance Organizing Agency), official announcement on the 18 October 2026 mandatory Halal deadline and covered product categories including Class A medical devices: https://bpjph.halal.go.id/read/tak-hanya-makanan-minuman-ini-jenis-produk-yang-wajib-bersertifikat-halal-mulai-18-oktober-2026
• Permenkes No. 62/2017 (Izin Edar Alat Kesehatan — official regulation text): https://peraturan.go.id/id/permenkes-no-62-tahun-2017
• Permenkes No. 11/2025 (current risk-based health-sector business-licensing standard): https://peraturan.go.id/id/permenkes-no-11-tahun-2025
• LPPOM MUI (accredited Halal Inspection Agency), staggered Class A/B/C/D Halal-certification timeline under PP 42/2024: https://halalmui.org/en/why-are-medical-devices-required-to-have-bpjph-halal-certification-starting-in-2026/
• BPOM drug registration portal (pharmaceutical-system reference, adjacent regulator): https://registrasiobat.pom.go.id
• Secondary regulatory-consultancy sources used for classification, timeline, fee, IVD, SaMD, license-holder structure, and TKDN detail (cross-checked against each other and against the official sources above where possible): https://omcmedical.com/blog/nie-registration-indonesia-medical-devices, https://omcmedical.com/blog/authorized-representative-indonesia-medical-devices, https://omcmedical.com/blog/indonesia-medical-device-registration-cost-idak-cdakb-nie, https://www.elendilabs.com/en/articles/idn-ivd-registration, https://andamanmed.com/indonesia-introduces-simplified-registration-class-a-medical-devices/, https://meddeviceguide.com/blog/indonesia-akd-halal-certification-cdakb-requirements-myth-check-guide, https://productregistrationindonesia.com/indonesia-medical-device-registration-process-with-asean-csdt-cheat-sheet/, https://www.freyrsolutions.com/blog/good-distribution-practices-gdps-for-medical-devices-in-indonesia, https://www.qualtechs.com/en-gb/article/indonesia-idak-vs-ipak-medical-device-licenses, https://insightof.id/medical-device-classification-indonesia/, https://insightof.id/registering-medical-device-software-in-indonesia/, https://meddeviceguide.com/blog/indonesia-ekatalog-medical-device-procurement-guide, https://www.trade.gov/market-intelligence/indonesia-medical-procurement-system
• Kalbe Farma: https://www.kalbe.co.id
• Bio Farma: https://www.biofarma.co.id
• Kimia Farma: https://www.kimiafarma.co.id

Access / verification date: 2026-08-17. Medical device registration ownership should be read through Kemenkes / Regalkes / AKL / NIE. Items marked 【待核验】 above (exact calendar dates for Class B/C/D Halal deadlines, scope of Halal exemptions, several commercial/service fee line items, current status of the simplified-notification SKU list under Permenkes 11/2025, and AI/algorithm-specific SaMD classification rules) were not independently confirmable in the accessible official text as of this date and should be reverified directly with Kemenkes / Regalkes / BPJPH, or your Indonesian license holder, before filing or before treating any date or figure on this page as a compliance deadline.